Drug Production Wuxi STA Breaks Ground for New Pharma Manufacturing Facility in USA
Wuxi STA recently conducted a breaking ground ceremony for establishing the firm’s second pharma manufacturing facility in the USA. The first phase of the project will provide formulation development, clinical and commercial drug product manufacturing services.
Shanghai/China – Wuxi STA, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), has recently announced the breaking ground ceremony for its new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware, USA. First announced in June 2021, this site will be Wuxi STA’s second facility in the United States, offering expanded capacity and greater flexibility to meet the needs of customers in the U.S. and around the world.
The new state-of-the-art facility will create approximately 500 full-time jobs by 2026. Phase I of the new campus will provide formulation development, clinical and commercial drug product manufacturing services for a variety of oral and injectable dosage forms, as well as packaging, labeling, storage and distribution services for clinical trial materials and commercial drug products.
Together with three other drug product manufacturing sites in Couvet (Switzerland), Wuxi City (China) and Shanghai (China), this new facility will further enhance the company’s global drug production capacity and capabilities.
The Wuxi STA Middletown facility is expected to begin operations in 2025.